Dr. Michael Becker, MD – Indianapolis, IN

  • SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia  

    Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR, Br J Haematol, 1/1/2014
  • Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myeloid leukemia  

    Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC, Mol Cancer Ther, 1/1/2014
  • Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells  

    Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes..., J Biol Chem, 1/22/2013
  • Join now to see all
  • You Might Also Like